Folforinox – pro
Several regimens can be utilized in metastatic pancreatic cancer. Among them is the more recently published Folforinox. The ESMO guideline says that the FOLFIRINOX protocol confers a significant improvement in the OS of patients with stage IV pancreatic cancer and can be considered as a novel therapeutic option for patients ≤75 years of age with a good PS (0 or 1) and a level of bilirubin ≤1.5 ULN. t is a fairly toxic regimen and hence, is the recommendation to use it for patients younger than 75 years of age. However, American guidelines, including NCCN, do not restrict it on the basis of age.
Davendra P.S. Sohal, Pamela B. Mangu et al, Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 34, no. 23 (August 2016) 2784-2796.
T. Seufferlein J.B. Bachet E. Van Cutsem P. Rougier on behalf of the ESMO Guidelines Working Group, Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Ann Oncol (2012) 23 (suppl_7): vii33-vii40.
NCCN, Panc-G, 1 2019